drugset / Trial / NCT00259753
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5. Cand5, a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
Timeline
- Start
- 2005-07
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bevasiranib | Unknown | 0.2 mg | Intravitreal |
| Subject | bevasiranib | Unknown | 1.5 mg | Intravitreal |
| Subject | bevasiranib | Unknown | 3 mg | Intravitreal |